CAT and breast cancer: Similarly, in the 40% FIELD CAPACITY treatment group, CAT activity was notably reduced by 24.43% with 0.4CMC-BC and 38.97% with 0.4GA3-BC, while 0.8CMC-BC and 0.8GA3-BC treatments led to substantial decreases of 51.56% and 63.33%, respectively, contrasted to the control (Fig. 5C).